Atopic dermatitis (AD) is a common inflammatory skin disease with high prevalence in both children (15–30%) and adults (2–10%), but limited data are available for older people. Elderly patients form a challenging group, as multiple comorbidities, associated polypharmacy and failures with previous treatments are common. We performed a retrospective observational study on elderly (≥ 65 years) patients treated with dupilumab, monoclonal antibody to the shared alpha subunit of the interleukin-4 and -13 receptor approved for the treatment of moderate-to-severe AD in adults.
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1111/ced.14260|
|Codice identificativo ISI:||WOS:000535009000001|
|Codice identificativo Scopus:||2-s2.0-85085549099|
|Titolo:||Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study|
|Appare nelle tipologie:||1.1 Articolo in rivista|